Table 2 Characteristics of the 17 OBs
Author-year | Study design | Intervention | Total, n | Age, median (IQR), year | Male, % | BMI, median (IQR), kg/m2 |
|---|---|---|---|---|---|---|
Castelnuovo-2021 [28] | Retrospective observational study | Therapeutic (TA): no dose data | 418 | / | / | / |
Prophylactic (PA): no dose data | 983 | / | / | / | ||
Elmelhat-2020 [29] | Observational retrospective study | Therapeutic (TA): enoxaparin (1 mg/kg BID) | 39 | 47.0 ± 10.5a | 74.4 | / |
Prophylactic (PA): enoxaparin (40 mg QD) | 20 | 47.7 ± 10.7a | 90.0 | / | ||
Gonzalez-Porras-2021 [30] | Observational study | Therapeutic (TA): enoxaparin (1 mg/kg BID) or bemiparin (115 IU anti-Xa/kg QD) | 120 | 76.3 ± 11.2a | 59.2 | 28.8 ± 4.8a |
Prophylactic (PA): enoxaparin (40 mg QD) or bemiparin (3500 UQD) | 410 | 71.7 ± 14.1a | 58.3 | 28.9 ± 5.3a | ||
Hamad-2021 [31] | Retrospective cohort study | Therapeutic (TA): enoxaparin (1 mg/kg BID) | 29 | 59 (51–65) | 69.0 | 28.3 (24.8–32.4) |
High-dose prophylaxis (PA): enoxaparin (40, 50 or 60 mg BID) | 17 | 59 (46–61) | 64.7 | 32.1 (28.4–40) | ||
Helms-2021 [32] | Bi-center cohort study | Therapeutic (TA): LMWH (100 IU/kg/12 h) | 71 | 64 (53–71) | 66.2 | 31 (27–34) |
Prophylactic (PA): LMWH (6000 IU/12 h) or UFH (200 IU/kg/24 h) | 108 | 61 (51–70) | 76.9 | 29 (26–33) | ||
Martinelli-2020 [33] | Observational cohort study | High dose (TA): no dose data | 127 | 60 (51–69) | 64.6 | 27.0 (24.2–30.2) |
Standard (PA): enoxaparin (40 to 60 mg QD) | 151 | 58 (49–66) | 65.6 | 28.1 (25.4–30.2) | ||
Battistoni-2021 [34] | European multicentric cohort study | Full dose (TA): LMWH (40 mg QD) | 102 | / | / | / |
Prophylactic (PA): LMWH (1 mg/kg BID) | 550 | / | / | / | ||
Ionescu-2020 [8] | Retrospective, multi-center cohort study | Therapeutic (TA): enoxaparin (1 mg/kg BID or 1.5 mg/kg QD).et | 998 | 68.2 ± 14.6a | 55.1 | 30.4 (14.5,73.3)b |
Prophylactic (PA): UFH (5000 U BID or TID) or enoxaparin (30–40 mg QD).et | 2121 | 64.4 ± 16.9a | 46.3 | 30.4 (12.9, 103.9)b | ||
Kaur-2020 [35] | Retrospective, multi-institutional cohort study | Therapeutic (TA): no dose data | 381 | / | / | / |
Prophylactic (PA): no dose data | 652 | / | / | / | ||
Canoglu-2020 [36] | Retrospective study | Therapeutic (TA): enoxaparin (1 mg/kg BID) | 56 | / | / | / |
Prophylactic (PA): enoxaparin (0.5 mg/kg BID) | 98 | / | / | / | ||
Qin-2021 [37] | A cohort study | Therapeutic (TA): LMWH (100 U/kg BID) | 77 | / | / | / |
Prophylaxis (PA): LMWH (3000–5000 U QD) | 109 | / | / | / | ||
Matli-2021 [38] | A propensity matched cohort study | Therapeutic (TA): no dose data | 31 | 62.55 ± 15.80a | 67.7 | / |
Prophylactic (PA): no dose data | 51 | 59.69 ± 17.04a | 58.8 | / | ||
Mennuni-2021 [39] | Observational study | Higher dose (TA): enoxaparin (>  4000 IU QD) | 149 | 70.2 ± 13.0a | 60.4 | / |
Prophylactic (PA): enoxaparin (4000 IU QD) | 287 | 71.2 ± 15.6a | 55.4 | / | ||
Kodama-2020 [40] | A Multi-Center Retrospective Cohort Study | Full dose (TA): no dose data | 82 | / | / | / |
Prophylactic (PA): no dose data | 498 | / | / | / | ||
Jonmarker-2020 [41] | Retrospective study | High dose (TA): tinzaparin (≥175 IU/kg QD) or dalteparin (≥200 IU/kg QD) | 37 | 63 (54–70) | 31 (83.8) | 28.4 (25.1–32.8) |
Low dose (PA): tinzaparin (2500–4500 IU QD) or dalteparin (2500–5000 IU QD) | 67 | 63 (52–71) | 59 (88.1) | 27.7 (25.5–30.6) | ||
Takayama-2021 [42] | Retrospective historical control study | Therapeutic (TA): UFH (APTT was 1.5–2.5 times as the control) | 33 | 62 (54–74) | 87.9 | / |
Prophylactic (PA): enoxaparin (40 mg BID) | 29 | 55 (52–65) | 86.8 | / | ||
Yu-2021 [43] | Retrospective cohort study | Therapeutic (TA): enoxaparin (1 mg/kg BID) or apixaban (≥5 mg BID).et | 298 | 61 (54–72) | 63.2 | / |
Prophylactic (PA): no dose data | 979 | 62 (50–75) | 56 | / |